Hospital Regional Universitario de Malaga | Hospital Civil - Rheumatology Department

Research site

(Unclaimed)

Location

Avenida Arroyo de los Angeles S/N, Malaga, Málaga, Spain

Site insights

Top conditions

Top treatments

Pembrolizumab

Magrolimab

Docetaxel

Topotecan

Lurbinectedin

Atezolizumab

Tislelizumab

Azacitidine

Tofacitinib

Aztreonam

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

33 of 78 total trials

A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC) (DeLLphi-301)

The main aim of this study is to:* evaluate safety and efficacy (per Response Evaluation Criteria in Solid Tumors version 1.1 \[RECIST 1.1\] by inves...

Active, not recruiting

Relapsed/Refractory Small Cell Lung Cancer

Drug: Tarlatamab

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (OLERO)

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche...

Active, not recruiting

Multiple Sclerosis

Drug: Ocrelizumab

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

The primary objective of this study is to compare progression-free survival (PFS) in participants who receive sotorasib with platinum doublet chemoth...

Enrolling

Non-Small Cell Lung Cancer (NSCLC)

Drug: Sotorasib

Drug: Pembrolizumab

A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors (COMMODORE 1)

A study designed to evaluate the safety of crovalimab with eculizumab in participants with PNH currently treated with complement inhibitors. This stu...

Active, not recruiting

Paroxysmal Nocturnal Hemoglobinuria

Drug: Eculizumab

Drug: Crovalimab

A Study of BAX 888 in Male Adults With Severe Hemophilia A

The main aim of this study is to check if there are side effects from BAX 888 and to determine the dose of BAX 888 for treating severe hemophilia A i...

Active, not recruiting

Hemophilia A

Drug: BAX 888

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

This study is designed to evaluate the safety and efficacy of ifinatamab deruxtecan (I-DXd) in combination with immune checkpoint inhibitor (ICI) ate...

Enrolling

Extensive Stage-small Cell Lung Cancer

Drug: Carboplatin

Drug: Ifinatamab deruxtecan

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (IDeate-Lung02)

This study was designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lun...

Enrolling

Small Cell Lung Cancer

Drug: Topotecan

Drug: Amrubicin

A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)

The main goal of this trial is to evaluate the safety and tolerability of mRNA-3745 via intravenous (IV) administration in adult and pediatric partic...

Enrolling

Glycogen Storage Disease

Drug: mRNA-3745

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (Morpheus Lung)

This study will evaluate the efficacy, safety, and pharmacokinetics of immunotherapy-based treatment combinations in participants with metastatic non...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Ipatasertib

Drug: XL092

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of ociperlimab + tislelizumab compared with that of pembrolizumab in adults with PD-...

Active, not recruiting

Non-small Cell Lung Cancer

NSCLC

Drug: Placebo

Drug: Tislelizumab

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) (AcceleRET-Lung)

This is an international, randomized, open-label, Phase 3 study designed to evaluate whether the potent and selective RET inhibitor, pralsetinib, imp...

Active, not recruiting

Neoplasms by Site

Neoplasms, Nerve Tissue

Drug: Carboplatin

Drug: Nab-Paclitaxel

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01)

The purpose of the study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in participa...

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: Tiragolumab

Drug: Atezolizumab

A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease

This study will be conducted to determine the preliminary efficacy of axatilimab in combination with ruxolitinib and to assess the contribution of ax...

Enrolling

Chronic Graft-versus-host-disease

Drug: Axatilimab

Drug: Corticosteroids

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) (FUSION)

In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is a 2-part...

Enrolling

Relapsing Forms of Multiple Sclerosis

Drug: BIIB091

Drug: DRF

Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer with EGFR or HER2 Mutation (WU-KONG1)

This study will treat patients with advanced NSCLC with EGFR or HER2 mutation who have progressed following prior therapy. This is the first time thi...

Active, not recruiting

Non-Small Cell Lung Cancer

Drug: Sunvozertinib

Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)

The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6)...

Active, not recruiting

Gastric Cancer

Gastroesophageal Junction Adenocarcinoma

Drug: Bemarituzumab

Drug: mFOLFOX6

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN281...

Enrolling

Melanoma

Drug: Cemiplimab

Drug: Placebo

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition...

Enrolling

Biliary Tract Cancer

HER2 Gene Mutation

Drug: Cisplatin

Drug: Gemcitabine

IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

Phase 3, multicenter, international, open-label, randomized, 2-arm trial investigating the safety and efficacy of IO102-IO103 in combination with pem...

Active, not recruiting

Unresectable Melanoma

Metastatic Melanoma

Drug: Pembrolizumab

Drug: IO102-IO103